drugset / Trial / NCT03128593

A Study of JR-141 in Patients With Mucopolysaccharidosis Type II

NCT03128593

Phase 1/2 Completed 14 enrolled JCR Pharmaceuticals Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

The purpose of this study in patients with mucopolysaccharidosis type II (MPS II) is below, * to collect the safety information of JR-141 * to evaluate the plasma pharmacokinetics of JR-141 * to explore the efficacy of JR-141 on MPS II-related central nervous system symptoms and general symptoms

Timeline

Start
2017-03-30
Primary completion
2017-10-04
Completion
2017-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PABINAFUSP ALFA Protein / enzyme biologic 0.01 mg/kg Intravenous
Subject PABINAFUSP ALFA Protein / enzyme biologic 2 mg/kg Intravenous